A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. John Swisher, StatCare Medical Group
Scroll to Top